NF2 BioSolutions Biobank — Researcher Sample Access
Who can apply: Qualified researchers anywhere in the world can apply to access NF2 samples at no cost.

We are a non-profit organization (Tax-ID 83-0940046) seeking a cure or preventative treatment for NF2 by vigorously supporting and advancing existing and next-generation biomedical technologies, such as gene therapy and immunotherapy.
NF2 Biosolutions centers its funding on Neurofibromatosis Type 2, with a stated aim of supporting existing and next-generation biomedical technologies to seek a cure or preventative treatment. Its recent grants show a clear preference for translational work: a $521,000 award to Mulberry Therapeutics for research stands out as the largest grant on file, while Yale University received multiple awards tied to tumor imaging model development. The foundation also backs therapeutic development beyond a single modality. Recent support includes funding for bacteriotherapy for NF2 at Mass Gen Development Office and research at Research Institute at Nationwide Ch, showing activity across academic and applied settings. Smaller awards also appear alongside larger ones, suggesting a mix of seed support and follow-on funding rather than a single fixed grant size. The organization funds researchers, labs, and related research resources, including biobank support, in service of NF2-focused therapeutic development. Its grant history points to a biomedical research funder working across gene therapy, cell therapy, immunotherapy, and related preclinical pathways for NF2 and schwannoma disorders.
One clear thread is research infrastructure. CHOP Research Institute received $7,983 for developing a tumor biobank for NF2, which fits the foundation’s emphasis on sample access and shared resources. Another area is model development: Yale University was funded for tumor imaging model work, with awards recorded in both 2023 and 2024 and a further grant in 2025. Therapeutic experimentation also appears repeatedly. Mass Gen Development Office received multiple grants for development of bacteriotherapy for NF2, including awards in 2023 and 2024. The portfolio also includes broad research support at Indiana University Research and William Cancer Institute PC, indicating that the foundation funds both specific tool-building projects and general NF2 research efforts.
Grant sizes cluster in the mid-five-figure range, with a p25 of $5,746, median of $32,818, and p75 of $44,630, while the distribution also includes a large outlier at $521,000. The recent record shows repeat funding to the same recipients across multiple years, including Yale University, Mass Gen Development Office, Research Institute at Nationwide Ch, and Merlin Therapeutics. That pattern suggests ongoing project support rather than one-time awards only. The foundation is an operating grantmaker rather than an individual-giving funder, and it also makes program-related investments. No application process is described in the provided data.
$1M
$622K
$226K
$317K
Most grants fall between $6K and $45K, with a median of $33K.
25th Percentile
$6K
Median
$33K
75th Percentile
$45K
About 21% of grants go to recipients in CT.
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Giving is national, and every recent grant in the sample went to a U.S. recipient. Connecticut is the top state by grant count, led by Yale University in New Haven. Pennsylvania also appears frequently, including awards in Philadelphia and King Of Prussia, and the HQ state accounts for 21% of grants. Other recipient locations include Boston, Columbus, Bloomington, Beverly Hills, Los Angeles, Minneapolis, and Wellesley Hills, showing a spread across major research centers rather than one region.
The foundation funds preclinical and translational research for Neurofibromatosis Type 2, with emphasis on gene therapy, cell therapy, toxicology studies, immunotherapy, and related novel therapeutic approaches. It also supports shared research resources such as biobanks and sample access.
Yes. Yale University, Mass Gen Development Office, Research Institute at Nationwide Ch, and Merlin Therapeutics each appear more than once in the recent grants list, indicating recurring support for some recipients and projects.
Typical awards are in the mid-five-figure range: p25 is $5,746, median grant size is $32,818, and p75 is $44,630. The recent record also includes both smaller awards under $10,000 and one much larger $521,000 grant.
The top state by grant count is Connecticut, with Yale University in New Haven appearing multiple times. Pennsylvania is also a frequent recipient state, and 21% of grants go to recipients in the foundation’s HQ state.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| RESEARCH INSTITUTE AT NATIONWIDE CH | COLUMBUS, OH | $60,380 | 2025 | RESEARCH |
| MASS GEN DEVELOPMENT OFFICE | BOSTON, MA | $60,000 | 2025 | DEVELOPMENT OF BACTERIOTHERAPY FOR NF2 |
| YALE UNIVERSITY | NEW HAVEN, CT | $36,351 | 2025 | TUMOR IMAGING MODEL |
| MERLIN THERAPEUTICS | KING OF PRUSSIA, PA | $5,791 | 2025 | RESEARCH |
| Mulberry Therapeutics | Wellesley Hills, MA | $521,000 | 2024 | research |
| Mass Gen Development Office | Boston, MA | $60,512 | 2024 | development of bacteriotherapy for NF2 |
| Indiana University Research | Bloomington, IN | $47,007 | 2024 | research |
| Yale University | New Haven, CT | $36,351 | 2024 | tumor imaging model |
| William Cancer Institute PC | Beverly Hills, CA | $35,436 | 2024 | research |
| Merlin Therapeutics | King Of Prussia, PA | $30,200 | 2024 | — |
| Cell Culture Company LLC | Minneapolis, MN | $1,838 | 2024 | research |
| Research Institute at Nationwide Ch | Columbus, OH | $1,000 | 2024 | research |
| University of California | Los Angeles, CA | $812 | 2024 | research |
| Yale University | New Haven, CT | $72,702 | 2023 | tumor imaging model |
| Institute for Cancer Research | Philadelphia, PA | $37,500 | 2023 | research |
| Mass Gen Development Office | Boston, MA | $20,000 | 2023 | development of bacteriotherapy for NF2 |
| CHOP Research Institute | Philadelphia, PA | $7,983 | 2023 | developing a tumor biobank for NF2 |
| University of California | Los Angeles, CA | $5,000 | 2023 | research |
RESEARCH INSTITUTE AT NATIONWIDE CH
$60,380RESEARCH
MASS GEN DEVELOPMENT OFFICE
$60,000DEVELOPMENT OF BACTERIOTHERAPY FOR NF2
YALE UNIVERSITY
$36,351TUMOR IMAGING MODEL
MERLIN THERAPEUTICS
$5,791RESEARCH
Mulberry Therapeutics
$521,000research
Mass Gen Development Office
$60,512development of bacteriotherapy for NF2
Indiana University Research
$47,007research
Yale University
$36,351tumor imaging model
William Cancer Institute PC
$35,436research
Merlin Therapeutics
$30,200Cell Culture Company LLC
$1,838research
Research Institute at Nationwide Ch
$1,000research
University of California
$812research
Yale University
$72,702tumor imaging model
Institute for Cancer Research
$37,500research
Mass Gen Development Office
$20,000development of bacteriotherapy for NF2
CHOP Research Institute
$7,983developing a tumor biobank for NF2
University of California
$5,000research
Current and upcoming funding from Nf2 Biosolutions that your nonprofit may be able to apply for.
Who can apply: Qualified researchers anywhere in the world can apply to access NF2 samples at no cost.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.